Ascentage Pharma Group International reported cash from operations of -$60.93M and free cash flow of -$58.10M for the quarter ended Dec 2025. This cash flow statement covers 3 quarters of results from Dec 2023 through Dec 2025, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Dec2023 | Dec2024 | Dec2025 |
|---|---|---|---|
| Operating Activities | |||
| Cash from OperationsCash from Ops. | -60.93M | ||
| Investing Activities | |||
| Capital ExpendituresCapex | -2.83M | ||
| Change in Acquisitions & DivestmentsChange Acquisitions | -5.64M | ||
| Cash from Investing ActivitiesCash from Investing | -99.33M | ||
| Financing Activities | |||
| Cash from Financing ActivitiesCash from Financing | 134.05M | ||
| Change in Capital Stock | |||
| Net Equity Issued and RepurchasedNet Equity Issued | 133.97M | ||
| Additional items | |||
| Exchange Rate EffectFX Effect | -0.51M | ||
| Change in Cash | -26.21M | ||
| Beginning Cash Balance | 144.17M | 124.33M | 125.92M |
| Free Cash FlowFCF | -58.10M | ||
| Net Cash FlowNCF | -26.21M |